An observational study in Cystic Fibrosis (CF), Cardiorespiratory Fitness and Inspiratory Muscle Strength, sponsored by Hacettepe University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Hacettepe University · Observational
Among 15 studies in Cystic Fibrosis by Hacettepe University — 1 open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Hacettepe University.
Among the 15 studies in Cystic Fibrosis by Hacettepe University, this one is the 5th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2023, is one of 12 observational ones, and was the 15th registered.
1,619 studies on the registry are indexed under Cystic Fibrosis; 199 are open to participants now.
Browse Cystic Fibrosis studies →1 of the 15 studies in Cystic Fibrosis by Hacettepe University is open now, in 1 country. Recruiting first, the newest first:
Hacettepe University · Sites in Turkey
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Of the 154 Cystic Fibrosis studies recruiting now, 95 (62%) set no upper age limit and 43 (28%) stop at 75 or younger; 84 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2023.
This study's enrollment of 50 is below the median of 85 across 503 observational studies indexed under Cystic Fibrosis.
Median enrollment 30 across the 3 interventional studies, 49 across the 12 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hacettepe University is the lead sponsor of 1,007 studies on the registry; 214 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Cystic Fibrosis by Hacettepe University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to examine and compare static and dynamic inspiratory muscle strength and cardiorespiratory fitness in adults with cystic fibrosis and their healthy peers.
The study will include individuals aged 18 and older who have been diagnosed with CF and are followed by Hacettepe University, as well as healthy individuals of similar age and sex.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
static inspiratory strength
maximal inspiratory pressure
Time frame: This measure takes 5 minutes.
dynamic inspiratory muscle strength
S-index
Time frame: This measure takes 10 minutes.
cardiorespiratory fitness
cardiopulmonary exercise test
Time frame: This measure takes 20 minutes.
Plan to share: Undecided — I have concerns about the retention of personal data, but the authors may consider it if there is a credible request.
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Nov 2025, 24 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.